pharmaceuticals

pharmaceuticals Articles

Johnson & Johnson shares dropped on Wednesday following the announcement that a jury has awarded $8 billion in damages to a man accusing the drugmaker of failing to warn about the side effects of...
Eli Lilly announced some good news for people suffering moderate to severe plaque psoriasis when it presented at the 5th Annual Maui Derm NP+PA Fall meeting.
One analyst issued a fairly bullish report in response to Johnson & Johnson's announcement of a $10 million settlement with two Ohio counties ahead of an upcoming opioid trial.
Merck has just announced that the FDA has accepted a couple new drug applications for review, including for a treatment for Clostridium difficile infections in children.
These three biotech stocks have upcoming clinical data and presentations that could be huge, and they could blast the stocks higher.
Catabasis Pharma shares jumped early on Tuesday after the firm announced that it had completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study. Specifically, the enrollment...
Dova Pharmaceuticals shares jumped on Monday after the firm announced that it would be acquired by Swedish Orphan Biovitrum, or Sobi. But are Dova investors getting enough out of this acquisition?
These four top large-cap pharmaceutical stocks for investors to consider all pay solid dividends and look like very solid fourth-quarter ideas.
Pfizer has announced positive top-line results from a second Phase 3 pivotal study evaluating abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.
Enanta Pharma shares dropped on Thursday after the company announced topline results from its Argon-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).
Achillion Pharma shares jumped on Wednesday after the firm announced that the FDA has granted Breakthrough Therapy designation for danicopan (ACH-4471).
PhaseBio Pharma shares jumped on Wednesday after the firm announced results from its midstage trial focused on novel therapies for cardiopulmonary orphan diseases.
The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Acadia shares made a handy gain on Monday after the firm announced positive results from an eight-week Phase 2 study evaluating pimavanserin as a therapy for Parkinson’s disease patients with...
Avadel Pharma shares jumped on Monday morning after the firm announced that the FDA has agreed to the company’s proposed amendments to a statistical analysis plan and protocol.